<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224587</url>
  </required_header>
  <id_info>
    <org_study_id>D1840M00017</org_study_id>
    <nct_id>NCT01224587</nct_id>
  </id_info>
  <brief_title>Magnetic Marker Monitoring (MMM) Study With Gel Matrix Tablets Under Fasting and Fed Conditions</brief_title>
  <acronym>MMM</acronym>
  <official_title>Characterisation of Gastrointestinal Transit of Four New Developed Gel Matrix Tablets With Different Erosion Rates by Means of MMM Measurement Under Fasting and Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to monitor the gastrointestinal transport of eroding gel matrix
      placebo tablets in healthy male volunteers under fasting and fed conditions. The method which
      is used is an imaging technique.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time from an administration of each of the placebo gel matrix tablets of each arm until Gastric Emptying Time (GET)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The time from an administration of each of the placebo gel matrix tablets of each arm until Colon Arrival Time (CAT)</measure>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Magnetic Marker Monitoring</condition>
  <condition>Gastrointestinal-transport</condition>
  <condition>Gastric Emptying Time</condition>
  <condition>Small Intestinal Transit Time</condition>
  <condition>Time for Colon Arrival</condition>
  <condition>Food Effect</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D1000078 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172),AstraZeneca,Mölndal, Sweden , under fasting condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D1000082 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fasting condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D1000083 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden ,under fasting condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden , under fasting condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D100083 marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca, Mölndal, Sweden , under fed condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D1000078</intervention_name>
    <description>Oral, one single dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D1000082</intervention_name>
    <description>Oral, one single dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D1000083</intervention_name>
    <description>Oral, one single dose</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D1000085</intervention_name>
    <description>Oral, one single dose</description>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ethnic origin: Caucasian

          -  Body-mass index (BMI): ≥ 19 kg/m² and ≤ 27 kg/m²

          -  Good health

          -  Written informed consent, after having been informed about benefits and potential
             risks of the trial

        Exclusion Criteria:

          -  Diseases which could influence the gastric emptying and gastrointestinal transport

          -  Diet which could influence the gastric emptying and gastrointestinal transport

          -  Surgery in the gastrointestinal tract which may interfere with the safety and
             transport of test product

          -  Ferromagnetic implants or any other magnetic disturbance, which can affect the
             Magnetic Marker Monitoring measurement

          -  Regular medical treatments which could affect the gastric emptying and
             gastrointestinal transport
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Donath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Socra Tec R&amp;D GmbH, Clinical Pharmacology Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Anschütz</last_name>
    <role>Study Chair</role>
    <affiliation>Socra Tec R&amp;D GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2010</study_first_posted>
  <last_update_submitted>November 3, 2010</last_update_submitted>
  <last_update_submitted_qc>November 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Imaging technique</keyword>
  <keyword>gastric transport through the gut</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

